Infectious Diseases – Conduct Research

Infectious Diseases & Vaccines

Advancing Global Health Through Clinical and Translational Research

Infectious diseases remain among the most significant threats to human health, driving global morbidity, mortality, and economic burden.

The emergence of new pathogens, antimicrobial resistance, and shifting epidemiological landscapes continue to challenge healthcare systems and scientific communities worldwide.

At Conduct Research, we are committed to advancing the prevention, diagnosis, and treatment of infectious diseases through scientifically rigorous and operationally efficient clinical trials.

Our multidisciplinary expertise spans vaccine development, antiviral and antibacterial therapeutics, immunomodulators, and novel biologics.

Therapeutic Expertise

Our dedicated infectious disease research team supports a wide range of programs, including both preventive and therapeutic interventions. Conduct Research partners with sponsors to design and deliver studies that meet the highest standards of data integrity, patient safety, and regulatory compliance.

Vaccine Development

Prophylactic and therapeutic vaccines against viral, bacterial, and parasitic pathogens.

Antimicrobial & Antiviral Agents

Novel anti-infective compounds, resistance mechanisms, and combination therapies.

Emerging & Re-emerging Pathogens

COVID-19, Zika, Ebola, dengue, RSV, influenza, and other outbreak-prone diseases.

Immunologic & Host-Targeted Therapies

Immunomodulators and adjuvants designed to enhance host response.

Clinical Trial Capabilities

Conduct Research provides end-to-end support across all phases of infectious disease and vaccine development, integrating operational excellence with scientific insight.

Phase I–IV Clinical Trials

Design and execution of first-in-human, dose-ranging, safety, efficacy, bridging, and post-marketing studies.

Regulatory Affairs & Strategy

Early engagement with Health Canada, FDA, EMA, and regional authorities to streamline submissions and approvals.

Data & Biomarker Integration

Immunogenicity, pharmacokinetic/pharmacodynamic (PK/PD), and correlates of protection analyses.

Rapid Study Activation in Outbreaks

Leveraging site readiness and accelerated contracting for time-sensitive and emergent disease contexts.

Operational Infrastructure

Site Partnerships

Collaboration with academic, hospital-based, and community research sites.

Centralized Data Management

Real-time electronic data capture (EDC), remote monitoring, and adaptive analytics.

Experienced Investigators

Infectious disease specialists, vaccinologists, and epidemiologists with proven expertise in protocol delivery.

Quality & Compliance Systems

GCP-aligned processes ensuring accuracy, transparency, and regulatory readiness.

Partner With Us

Conduct Research supports pharmaceutical, biotech, and public health organizations in advancing infectious disease and vaccine programs from concept to market.

Start your new trial, Let's do it!

Scientific & Medical Affairs

Conduct Research’s scientific and medical affairs unit provides strategic input at every stage of study planning and execution:

Protocol design and endpoint development
Selection and validation of immunologic assays
Risk-benefit assessment and data review
Medical monitoring and pharmacovigilance
Clinical data interpretation and publication support

Our experts also collaborate on translational research initiatives that connect early discovery with late-phase clinical outcomes.

Strategic Advantages

Partnering with Conduct Research offers sponsors measurable advantages in infectious disease and vaccine development:

Scientific depth across virology, immunology, and epidemiology
Accelerated timelines through adaptive design and rapid start-up models
Integrated SMO–CRO model ensuring site performance and data consistency
Regulatory and ethical expertise supporting global submissions
Commitment to diversity and equity in participant recruitment and representation